logo-loader
viewGlaxoSmithKline PLC

GlaxoSmithKline PLC boss to quit in 2017 amid shake-up talk

Drug giant says Andrew Witty will go in March 2017

23045605462_63d7ef9fce_o.jpg
There has been market talk that Glaxo could either be taken over by a rival or broken up

--- Updates with broker comment and latest share price ---

Drug giant GlaxoSmithKline PLC (LON:GSK) has said its chief executive is stepping down, paving the way for a potential shake-up.

Glaxo said Andrew Witty would retire in at the end of March 2017, effectively confirming speculation late last month that the company had started looking for a successor.

The announcement is likely to be seen as a move by the company to placate those investors who have been calling for a break-up of Glaxo into its various parts.

There has been speculation that Glaxo could either be taken over by a rival or broken up, with its consumer healthcare division being a possible target.

Prominent fund manager Neil Woodford has demanded such a move, but Witty has responded that he believes the company is better staying intact.

Broker Killik & Co said: "This announcement signals the potential for a significant change in corporate strategy.

"An incoming chief executive, especially if an external hire, could push for a break-up of the company, or if results are disappointing, could place the dividend at risk."

Shares in Glaxo fell 1.84% to 1386 following the news.

GlaxoSmithKline is the ninth FTSE 100 company to be planning a change of chief executive in the next two years, according to AJ Bell investment director Russ Mould.

Whitbread (LON:WTB) has already installed Alison Brittain as chief executive, while M&S (LON:MKS), Bunzl (LON:BNZL), Admiral (LON:ADM), Babcock (LON:BAB), Wolseley (LON:WOS) and Rio Tinto (LON:RIO) will change theirs this year.

Glaxo and possibly BAE Systems (LON:BA.) are set to change their chief executives next year.

Mould said: "On the whole, a firm’s share price can welcome a new boss.

"On average, for the changes already seen, the company’s share price has increased by 16.4% to date.

"This compares to a FTSE 100 average decline of 3.6% - so outperformance of 20 percentage points."

In a statement confirming his plan to go next year, Witty said "very significant progress" last year had laid the foundations for Glaxo to achieve its medium-term outlook.

Witty said: “By next year, I will have been chief executive for nearly 10 years and I believe this will be the right time for a new leader to take over.

"In making this decision, it has been important to me that the board have the time to conduct a full and proper process and that we sustain the momentum of our current business performance."

Glaxo's chairman Philip Hampton said: "Andrew’s retirement next year will represent the culmination of 32 years of service and leadership to Glaxo and the industry.

"In the meantime, we will now start a formal process to appoint his successor, whilst also ensuring the Group remains focussed on execution of its strategy to drive growth and performance.”

Quick facts: GlaxoSmithKline PLC

Price: 1814 GBX

LSE:GSK
Market: LSE
Market Cap: £90.51 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging achieves positive phase III results in two...

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI)...

1 hour, 2 minutes ago

3 min read